Mark Leeds, D.O.
Mark Leeds, D.O.
Beyond Ozempic: Innovative Medications Shaping the Future of Weight Loss
Beyond Ozempic: Innovative Medications Shaping the Future of Weight Loss
Beyond Ozempic: Innovative Medications Shaping the Future of Weight Loss
Friday 4th October 2024
Discover how innovative weight loss medications like GLP-1 receptor agonists are revolutionising treatment beyond Ozempic.
10 minutes
Informative
Engaging
Hopeful
Educational
Supportive
About this podcast
Author:
Mark Leeds, D.O.
Overview:
Categories:
Innovative Treatments & Recovery Paths
Sobriety Toolkit
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
381 (View all)
Do you want to link to this podcast?
Get the buttons here!Beyond Ozempic: The Future of Weight Loss Medications
Episode Overview
- GLP-1 receptor agonists help regulate appetite and reduce calorie intake.
- Semaglutide shows impressive weight loss results with up to 15% body weight reduction.
- Terzepatide targets both GLP-1 and GIP receptors for enhanced benefits.
- Rita Truetide offers a triple action mechanism for comprehensive weight management.
- Orphergliprin provides the benefits of GLP-1 receptor agonists in an oral pill form.
These medications target areas of the brain responsible for appetite regulation and food intake.
In this episode of 'Mark Leeds DO On Addiction Treatment And Addiction Recovery', Dr. Mark Leeds takes a fascinating dive into the innovative world of weight loss medications beyond Ozempic. The episode shines a light on GLP-1 receptor agonists and their game-changing role in weight management. These medications target the brain areas responsible for appetite, helping individuals feel fuller for longer and reducing calorie intake. Dr.
Leeds explains how these drugs also slow down gastric emptying, enhancing the feeling of satiety - a real win-win for anyone struggling with weight loss. Dr. Leeds discusses the groundbreaking impact of semaglutide, originally developed for type 2 diabetes, which has shown impressive weight loss results in clinical trials. Patients have seen up to a 15% reduction in body weight, making it a popular choice among healthcare providers. The convenience of its once-weekly dosing is another bonus.
Another highlight is terzepatide, which offers a dual approach by targeting both GLP-1 and GIP receptors. This unique mechanism has shown even greater benefits in clinical trials, surpassing other medications. Dr. Leeds also covers established players like dilaglutide and liraglutide, which continue to be reliable options in the weight management arena. The episode introduces listeners to Rita Truetide, an innovative medication with a triple action mechanism targeting GIP, GLP-1, and glucagon receptors.
Early trials show promising results, not just in weight loss but also in managing blood sugar levels and improving lipid profiles. Finally, Dr. Leeds talks about Orphergliprin, an oral GLP-1 receptor agonist that could revolutionise treatment accessibility. This pill form could break down barriers for those hesitant about injections. This episode is a must-listen if you're curious about the future of weight loss treatments and how these medications could fit into comprehensive weight management programs. Dr.
Leeds' expertise and passion for the subject make it both informative and engaging. Why not give it a listen and see how these innovations could change the landscape of weight management?